733 related articles for article (PubMed ID: 12684669)
1. Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer.
Chen Y; Wang J; Fraig MM; Henderson K; Bissada NK; Watson DK; Schweinfest CW
Int J Oncol; 2003 May; 22(5):1033-43. PubMed ID: 12684669
[TBL] [Abstract][Full Text] [Related]
2. Defects of DNA mismatch repair in human prostate cancer.
Chen Y; Wang J; Fraig MM; Metcalf J; Turner WR; Bissada NK; Watson DK; Schweinfest CW
Cancer Res; 2001 May; 61(10):4112-21. PubMed ID: 11358834
[TBL] [Abstract][Full Text] [Related]
3. DNA mismatch repair enzyme activity and gene expression in prostate cancer.
Yeh CC; Lee C; Dahiya R
Biochem Biophys Res Commun; 2001 Jul; 285(2):409-13. PubMed ID: 11444857
[TBL] [Abstract][Full Text] [Related]
4. Elevated levels of the mismatch repair protein PMS2 are associated with prostate cancer.
Norris AM; Woodruff RD; D'Agostino RB; Clodfelter JE; Scarpinato KD
Prostate; 2007 Feb; 67(2):214-25. PubMed ID: 17044039
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC).
van der Klift H; Wijnen J; Wagner A; Verkuilen P; Tops C; Otway R; Kohonen-Corish M; Vasen H; Oliani C; Barana D; Moller P; Delozier-Blanchet C; Hutter P; Foulkes W; Lynch H; Burn J; Möslein G; Fodde R
Genes Chromosomes Cancer; 2005 Oct; 44(2):123-38. PubMed ID: 15942939
[TBL] [Abstract][Full Text] [Related]
6. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer.
Truninger K; Menigatti M; Luz J; Russell A; Haider R; Gebbers JO; Bannwart F; Yurtsever H; Neuweiler J; Riehle HM; Cattaruzza MS; Heinimann K; Schär P; Jiricny J; Marra G
Gastroenterology; 2005 May; 128(5):1160-71. PubMed ID: 15887099
[TBL] [Abstract][Full Text] [Related]
8. Biallelic somatic inactivation of the mismatch repair gene MLH1 in a primary skin melanoma.
Castiglia D; Pagani E; Alvino E; Vernole P; Marra G; Cannavò E; Jiricny J; Zambruno G; D'Atri S
Genes Chromosomes Cancer; 2003 Jun; 37(2):165-75. PubMed ID: 12696065
[TBL] [Abstract][Full Text] [Related]
9. Microsatellite instability testing in colorectal carcinoma: choice of markers affects sensitivity of detection of mismatch repair-deficient tumors.
Hatch SB; Lightfoot HM; Garwacki CP; Moore DT; Calvo BF; Woosley JT; Sciarrotta J; Funkhouser WK; Farber RA
Clin Cancer Res; 2005 Mar; 11(6):2180-7. PubMed ID: 15788665
[TBL] [Abstract][Full Text] [Related]
10. Microsatellite instability in colorectal carcinoma. The comparison of immunohistochemistry and molecular biology suggests a role for hMSH6 [correction of hMLH6] immunostaining.
Rigau V; Sebbagh N; Olschwang S; Paraf F; Mourra N; Parc Y; Flejou JF
Arch Pathol Lab Med; 2003 Jun; 127(6):694-700. PubMed ID: 12741892
[TBL] [Abstract][Full Text] [Related]
11. Isolated loss of PMS2 expression in colorectal cancers: frequency, patient age, and familial aggregation.
Gill S; Lindor NM; Burgart LJ; Smalley R; Leontovich O; French AJ; Goldberg RM; Sargent DJ; Jass JR; Hopper JL; Jenkins MA; Young J; Barker MA; Walsh MD; Ruszkiewicz AR; Thibodeau SN
Clin Cancer Res; 2005 Sep; 11(18):6466-71. PubMed ID: 16166421
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer.
Caldés T; Godino J; Sanchez A; Corbacho C; De la Hoya M; Lopez Asenjo J; Saez C; Sanz J; Benito M; Ramon Y Cajal S; Diaz-Rubio E
Oncol Rep; 2004 Sep; 12(3):621-9. PubMed ID: 15289847
[TBL] [Abstract][Full Text] [Related]
13. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma.
Geisler JP; Goodheart MJ; Sood AK; Holmes RJ; Hatterman-Zogg MA; Buller RE
Cancer; 2003 Nov; 98(10):2199-206. PubMed ID: 14601090
[TBL] [Abstract][Full Text] [Related]
14. Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells.
Mihaylova VT; Bindra RS; Yuan J; Campisi D; Narayanan L; Jensen R; Giordano F; Johnson RS; Rockwell S; Glazer PM
Mol Cell Biol; 2003 May; 23(9):3265-73. PubMed ID: 12697826
[TBL] [Abstract][Full Text] [Related]
15. Mismatch repair gene expression and genetic instability in testicular germ cell tumor.
Velasco A; Riquelme E; Schultz M; Wistuba II; Villarroel L; Pizarro J; Berlin A; Ittmann M; Koh MS; Leach FS
Cancer Biol Ther; 2004 Oct; 3(10):977-82. PubMed ID: 15467433
[TBL] [Abstract][Full Text] [Related]
16. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer.
Southey MC; Jenkins MA; Mead L; Whitty J; Trivett M; Tesoriero AA; Smith LD; Jennings K; Grubb G; Royce SG; Walsh MD; Barker MA; Young JP; Jass JR; St John DJ; Macrae FA; Giles GG; Hopper JL
J Clin Oncol; 2005 Sep; 23(27):6524-32. PubMed ID: 16116158
[TBL] [Abstract][Full Text] [Related]
17. Role for mismatch repair proteins Msh2, Mlh1, and Pms2 in immunoglobulin class switching shown by sequence analysis of recombination junctions.
Schrader CE; Vardo J; Stavnezer J
J Exp Med; 2002 Feb; 195(3):367-73. PubMed ID: 11828012
[TBL] [Abstract][Full Text] [Related]
18. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.
Schiemann U; Müller-Koch Y; Gross M; Daum J; Lohse P; Baretton G; Muders M; Mussack T; Kopp R; Holinski-Feder E
Digestion; 2004; 69(3):166-76. PubMed ID: 15118395
[TBL] [Abstract][Full Text] [Related]
19. Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of the small intestine.
Planck M; Ericson K; Piotrowska Z; Halvarsson B; Rambech E; Nilbert M
Cancer; 2003 Mar; 97(6):1551-7. PubMed ID: 12627520
[TBL] [Abstract][Full Text] [Related]
20. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer.
Fallik D; Borrini F; Boige V; Viguier J; Jacob S; Miquel C; Sabourin JC; Ducreux M; Praz F
Cancer Res; 2003 Sep; 63(18):5738-44. PubMed ID: 14522894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
